Chemomab Therapeutics reported net income of $2.17M for the quarter ended Jun 2026. This income statement covers 35 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.85M | 2.85M | 2.85M | 2.86M | 2.86M | 2.91M | 2.91M | 2.94M | 4.71M | 7.19M | |||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.49M | 2.38M | 2.75M | 2.91M | 5.42M | 5.89M | 6.89M | 5.02M | 3.38M | 3.10M | 3.15M | 2.93M | 2.84M | 2.41M | 2.49M | 1.29M | 0.96M | 1.09M | 0.93M | 1.14M | |||||||||||||||
| Selling, General & AdministrativeSG&A | 1.40M | 2.64M | 2.58M | 3.34M | 2.89M | 2.75M | 2.16M | 3.17M | 0.99M | 0.75M | 0.90M | 0.84M | 0.87M | 0.80M | 0.99M | 0.97M | 0.88M | 0.88M | 0.93M | 1.10M | |||||||||||||||
| Restructuring CostsRestructuring | |||||||||||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | |||||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 2.89M | 5.02M | 5.32M | 6.25M | 8.32M | 8.64M | 9.05M | 8.20M | 4.37M | 3.85M | 4.05M | 3.77M | 3.71M | 3.21M | 3.49M | 2.26M | 1.84M | 1.97M | 1.85M | 2.24M | |||||||||||||||
| Operating IncomeOp. Inc | |||||||||||||||||||||||||||||||||||
| EBIT | -2.97M | 19.92M | -5.10M | 7.21M | 7.84M | 7.88M | 8.73M | 7.68M | 3.90M | 2.99M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.48M | -0.24M | -0.38M | -0.26M | -0.23M | -0.43M | |||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.38M | 0.32M | 0.26M | -0.23M | -0.43M | 0.18M | 0.14M | 0.23M | -0.25M | 0.16M | 0.20M | 0.10M | -0.10M | 0.08M | 0.08M | ||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | |||||||||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||
| EBT | -2.97M | 19.92M | -5.10M | 6.73M | 8.08M | 8.26M | 8.73M | 7.94M | 4.14M | 3.42M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Tax ProvisionsTaxes | -0.54M | 0.01M | 0.02M | 0.03M | -0.06M | ||||||||||||||||||||||||||||||
| Profit After TaxPAT | -2.97M | 9.92M | -5.10M | 6.19M | 8.08M | 8.27M | -8.75M | 7.97M | 4.08M | -45.02M | -3.87M | -3.63M | 3.48M | 2.96M | -3.32M | 2.06M | 1.74M | 1.87M | -1.77M | 2.17M | |||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -2.97M | 19.92M | -5.10M | 7.28M | 8.08M | 8.25M | 8.71M | 7.90M | 4.19M | 3.42M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -2.97M | 19.92M | -5.10M | 7.28M | 8.08M | 8.25M | 8.71M | 7.90M | 4.19M | 3.42M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -2.97M | 19.92M | -5.10M | 7.28M | 8.08M | 8.25M | 8.71M | 7.90M | 4.19M | 3.42M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Net Income towards Common StockholdersNet Income | -2.97M | 19.92M | -5.10M | 7.28M | 8.08M | 8.25M | 8.71M | 7.90M | 4.19M | 3.42M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||
| EPS (Basic) | -1.04 | 7.68 | -1.79 | 2.55 | 2.83 | 2.90 | 3.15 | 2.86 | 1.52 | 1.16 | 1.32 | 1.24 | 1.19 | 0.66 | 0.74 | 0.46 | 0.39 | 0.29 | 0.28 | 0.34 | |||||||||||||||
| EPS (Diluted) | -1.04 | 7.68 | -1.79 | 2.55 | 2.83 | 2.90 | 3.15 | 2.86 | 1.52 | 1.16 | 1.32 | 1.24 | 1.19 | 0.66 | 0.74 | 0.46 | 0.39 | 0.29 | 0.28 | 0.34 | |||||||||||||||
| Shares Outstanding | 2.85M | 2.59M | 2.85M | 2.85M | 2.86M | 2.84M | 2.76M | 2.76M | 2.76M | 2.94M | 2.94M | 2.94M | 2.94M | 4.49M | 4.49M | 4.49M | 4.49M | 6.38M | 6.38M | 6.38M | |||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.85M | 2.59M | 2.85M | 2.85M | 2.86M | 2.84M | 2.76M | 2.76M | 2.76M | 2.94M | 2.94M | 2.94M | 2.94M | 4.49M | 4.49M | 4.49M | 4.49M | 6.38M | 6.38M | 6.38M | |||||||||||||||
| EBITDA | -2.97M | 19.92M | -5.10M | 7.21M | 7.84M | 7.88M | 8.73M | 7.68M | 3.90M | 2.99M | 3.87M | 3.63M | 3.48M | 2.96M | 3.32M | 2.06M | 1.74M | 1.87M | 1.77M | 2.17M | |||||||||||||||
| Interest ExpensesInt Expense | 0.48M | -0.24M | -0.38M | -0.26M | -0.23M | -0.43M | |||||||||||||||||||||||||||||
| Tax Rate | -8.08 | 0.12 | 0.24 | 0.43 | -1.33 |